Qian Li, Chen Wenyan, Wang Shaoqing, Liu Yang, Jia Xiaoqin, Fu Yi, Gong Weijuan, Tian Fang
Laboratory of Immunology, Yangzhou University School of Medicine, Yangzhou, China.
Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, China.
Cent Eur J Immunol. 2017;42(3):223-230. doi: 10.5114/ceji.2017.70962. Epub 2017 Oct 30.
Inappropriate activation of toll-like receptor 3 (TLR3) has been implicated in the pathogenesis of autoimmune diseases, so the negative regulation of TLR3-triggered immune response has received increasing attention. Nonpathogenic immune complex (IC) has been used as treatment for many inflammatory and autoimmune diseases. However, the role of IC in the regulation of TLR3-triggered immune responses and the underlying mechanisms need to be investigated. In this study we demonstrate that IC or intravenous immunoglobulin (Ig) stimulation of B cells attenuates polyinosinic:polycytidylic acid (poly I:C)-induced CD40 expression; IC, but not Ig, can significantly inhibit poly I:C-induced pro-inflammatory tumour necrosis factor α (TNF-α) production by B cells. Moreover, IC/Ig stimulation does not alter the expression of TLR3 in B cells. Further experiments suggest that receptor for the Fc portion of IgGIIb (FcγRIIb) is involved in the suppressive effect of IC on TLR3-mediated TNF-α production, but not CD40 expression. Thus, we provide a new means of negative regulation of TLR3-triggered immune responses in B cells via FcγRIIb, and we provide a new mechanistic explanation of the therapeutic effect of nonpathogenic IC on inflammatory or autoimmune diseases.
Toll样受体3(TLR3)的不适当激活与自身免疫性疾病的发病机制有关,因此TLR3触发的免疫反应的负调控受到越来越多的关注。非致病性免疫复合物(IC)已被用于治疗多种炎症性和自身免疫性疾病。然而,IC在调节TLR3触发的免疫反应中的作用及其潜在机制仍有待研究。在本研究中,我们证明IC或静脉注射免疫球蛋白(Ig)刺激B细胞可减弱聚肌苷酸:聚胞苷酸(poly I:C)诱导的CD40表达;IC而非Ig可显著抑制B细胞中poly I:C诱导的促炎性肿瘤坏死因子α(TNF-α)的产生。此外,IC/Ig刺激不会改变B细胞中TLR3的表达。进一步的实验表明,IgGIIb的Fc部分受体(FcγRIIb)参与了IC对TLR3介导的TNF-α产生的抑制作用,但不参与对CD40表达的抑制作用。因此,我们提供了一种通过FcγRIIb对B细胞中TLR3触发的免疫反应进行负调控的新方法,并且我们对非致病性IC对炎症性或自身免疫性疾病的治疗作用提供了一种新的机制解释。